HUTCHMED (China) Limited (HCM) wird mit einem nachlaufenden KGV von gehandelt 5.7, erwartetes KGV von 47.6. Die nachlaufende Gewinnrendite beträgt 17.49%, erwartete Gewinnrendite 2.10%. PEG 0.01 (Peter Lynch unterbewertet ≤1,0). Die Graham-Zahl beträgt $4.12.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 81/100 mit 4/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | 138.5 | -1.06 | 8.80 | 7.50 | - |
| 2017 | -189.9 | 0.59 | 11.00 | 21.05 | - |
| 2018 | -41.0 | -0.27 | 7.89 | 14.33 | - |
| 2019 | -31.5 | -0.69 | 11.59 | 16.29 | - |
| 2020 | -35.5 | -2.84 | 9.23 | 19.61 | - |
| 2021 | -28.6 | -0.73 | 5.64 | 15.62 | 1.79% |
| 2022 | -6.9 | -0.10 | 4.10 | 5.87 | 3.49% |
| 2023 | 30.5 | -0.24 | 4.21 | 3.67 | - |
| 2024 | 65.3 | -1.03 | 3.24 | 3.91 | - |
| 2025 | 5.0 | 0.00 | 1.85 | 4.16 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $0.50 | $216.08M | $11.7M | 5.4% |
| 2017 | $-0.22 | $241.2M | $-26.74M | -11.1% |
| 2018 | $-0.55 | $214.11M | $-74.81M | -34.9% |
| 2019 | $-1.10 | $204.89M | $-144.38M | -70.5% |
| 2020 | $-1.40 | $227.98M | $-194.56M | -85.3% |
| 2021 | $-1.45 | $356.13M | $-227.66M | -63.9% |
| 2022 | $-2.40 | $426.41M | $-410.14M | -96.2% |
| 2023 | $0.58 | $838M | $100.78M | 12% |
| 2024 | $0.22 | $630.2M | $37.73M | 6% |
| 2025 | $2.60 | $549.96M | $458.12M | 83.3% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $0.32 | $0.19 – $0.44 | $640.33M | $605.44M – $716.77M | 4 |
| 2027 | $0.46 | $0.43 – $0.53 | $741.92M | $701.5M – $830.49M | 3 |
| 2028 | $0.60 | $0.56 – $0.69 | $843.53M | $797.57M – $944.23M | 1 |
| 2029 | $0.88 | $0.82 – $1.02 | $1.05B | $996.98M – $1.18B | 1 |
| 2030 | $1.17 | $1.09 – $1.35 | $1.18B | $1.12B – $1.33B | 1 |
